Common Diagnosis
Prostate Cancer
A new prostate cancer diagnosis naturally raises big questions. How serious is it? Does it need treatment now? Can it be watched? The answer depends less on the word "cancer" by itself and more on the risk level of the cancer.
(placeholder)
Prostate Cancer at a Glance
What Matters Most
- Not all prostate cancer behaves the same
- Risk level drives the conversation
- There is usually time to understand the options
- Treatment depends on goals and trade-offs
Common Paths
- Active surveillance
- Staging when risk is higher
- Robotic prostatectomy
- Radiation therapy
Key Questions
- Can this safely be watched?
- Do I need treatment now?
- How do surgery and radiation differ?
- What recovery should I expect?
The Most Important Thing to Remember
Prostate cancer is not one disease. Some prostate cancers are low grade and not immediately life-threatening. Others are more aggressive and deserve staging and treatment discussion.
A treatment decision usually does not need to be made at the biopsy follow-up visit. The first step is understanding the risk category and what options are reasonable.
What a New Diagnosis Means
Hearing "prostate cancer" is scary, but the diagnosis does not tell the whole story. The grade of the cancer, PSA, biopsy findings, and overall clinical picture help determine whether the cancer appears low risk, intermediate risk, or high risk.
Risk level changes the conversation. Some patients are candidates for active surveillance. Others need staging and a treatment discussion. The goal is to match the plan to the behavior of the cancer, not simply react to the word cancer.
Why Risk Level Matters
Risk level is what turns a frightening diagnosis into a clearer decision. Low-risk, favorable intermediate-risk, unfavorable intermediate-risk, and high-risk prostate cancer are not the same office conversation.
Low-Risk Disease
Many low-risk prostate cancers can be watched carefully with active surveillance instead of treated immediately.
Favorable Intermediate Risk
Selected favorable intermediate-risk cancers may still be candidates for surveillance, depending on the full clinical picture.
Unfavorable Intermediate Risk
This is often the dividing line where surveillance falls away and staging plus treatment discussion becomes more appropriate.
High-Risk Disease
Higher-risk prostate cancer should not be minimized. It usually requires staging and a serious discussion about treatment.
Taking Time to Decide
A treatment decision usually does not need to be made at the biopsy follow-up visit. Many patients need time to go home, process the information, write down questions, and come back for another discussion.
Active Surveillance
Active surveillance is not doing nothing. It is structured follow-up for prostate cancers that appear safe to watch. It is most commonly considered for low-risk disease and selected favorable intermediate-risk disease.
The usual pattern includes PSA testing and MRI in between biopsies, with a repeat biopsy within the first year and then usually every 2–3 years. The purpose is to avoid unnecessary treatment while still watching closely enough to act if the cancer changes.
Progression is mainly determined by repeat biopsy. PSA changes can matter, but PSA can also fluctuate, so it is interpreted in context.
When Staging Is Needed
Staging means looking for evidence that cancer has spread beyond the prostate. It is not necessary for every new diagnosis, but it becomes more important as risk increases.
PSMA PET is generally used for unfavorable intermediate-risk disease or higher. For many patients, that is part of the shift from "Can this be watched?" to "What treatment path gives the best chance of cure?"
Surgery Versus Radiation
For localized prostate cancer that needs treatment, surgery and radiation often offer similar long-term cure. The decision is usually about trade-offs, recovery, side effects, and what matters most to the patient. Age matters, but overall health matters just as much as age.
For high-risk localized prostate cancer, surgery is often favored first because recurrence after surgery can still be treated with salvage radiation. Salvage prostatectomy after radiation is much more difficult and has higher complication rates.
Robotic Prostatectomy
Surgery removes the prostate and provides full pathology. It also preserves radiation as a salvage option later if the cancer comes back.
Radiation Therapy
Radiation can be an excellent treatment option for localized prostate cancer. Detailed radiation side-effect counseling is best reviewed with the radiation oncologist.
The Main Difference
Surgery gives more information after treatment because the prostate is removed and examined. Radiation treats the prostate without an operation.
Shared Decision-Making
There is often more than one reasonable option. Good counseling means understanding what each treatment asks of the patient.
What to Expect From Robotic Prostatectomy
Robotic prostatectomy is surgery to remove the prostate. The big recovery topics are the catheter, activity restrictions, urinary control, and erectile recovery. Most patients stay overnight and go home the next morning.
Many patients use little or no narcotic pain medication beyond the first night or two. Most are up walking and able to use stairs shortly after surgery.
Catheter
A urinary catheter is usually needed after surgery for about 10–12 days while the connection between the bladder and urethra heals.
Activity
No heavy lifting or strenuous activity for 6 weeks is part of the usual recovery counseling after prostatectomy.
Urinary Control
Urinary control usually improves faster and more predictably than erectile function, though recovery is still different for each patient.
Erectile Recovery
Erectile recovery is variable and can take up to 2 years. It is one of the important trade-offs to discuss before choosing surgery.
Common Misconceptions
All Prostate Cancers Behave the Same
They do not. Risk level is what determines whether surveillance, staging, or treatment is the right next conversation.
Treatment Must Be Chosen Immediately
A treatment decision usually does not need to be made at the biopsy follow-up visit. Understanding the risk level comes first.
Surveillance Means Ignoring Cancer
Active surveillance is structured follow-up with PSA, MRI when able to obtain, and repeat biopsies. It is a plan, not neglect.
Surgery Is Always Better Than Radiation
For localized disease, surgery and radiation often offer similar long-term cure. The right choice depends on trade-offs and patient priorities.
My Perspective
The first job after a new diagnosis is to make the cancer less abstract. What risk category is it? Can it be watched? Does it need staging? If treatment is needed, what trade-offs come with surgery and radiation?
The goal is not to rush a patient into a decision. It is to understand the seriousness of the cancer and choose a plan that fits the disease and the patient.